Treatment of colorectal cancer with and without bevacizumab: A phase III study

Oncology

Volumn 78, Issue 5-6, 2010, Pages 376-381

  Stathopoulos, G P ^a   Batziou, C ^a   Trafalis, D ^a   Koutantos, J ^a   Batzios, S ^a   Stathopoulos, J ^a   Legakis, J ^a   Armakolas, A ^a  

^a Errikos Dunant Hospital   (Greece)

Author keywords

Bevacizumab; Colorectal cancer

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; FLUOROURACIL; FLUOROURACIL PLUS IRINOTECAN; FOLINIC ACID; IRINOTECAN; ONDANSETRON; OXALIPLATIN; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL ADENOCARCINOMA; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; INTESTINE PERFORATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TOXICITY; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; HYPERTENSION; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77956083776     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320520     Document Type: Article

References (31)

1. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997; 19: 4-25.
2. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
3. Presta LG, Chen H, O' Connor SJ, Chisholm VY, Meng G: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599.
4. Jubb AM, Pham TQ, Handy AM, Frantz GD, Peale FV, Wu TD, Koeppen HW, Hillan KJ: Expression of vascular endothelial growth factor, hypoxia-inducible factor 1a and carbonic anhydrase IX in human tumours. J Clin Pathol 2004; 57: 504-512.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hamsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
6. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DP, Hartford AC, Fischman AG, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK: Direct evidence that VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Natl Med 2004; 10: 145-147.
7. Gerber HP, Ferrara N: A specific approach to VEGF inhibition. Cancer Res 2005; 65: 671-680.
8. Berger MM: Fluorescent inhibitors for IspF. Nature 2002; 418: 785-789.
9. Yuan Y, Sherman DR, Barry CE: Exploring drug-induced alteration in gene expression. Proc Natl Acad Sci USA 2002; 14321-14326.
10. Rougier P, van Custem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques P: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
11. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammer H, Topham CA, Awad L, Jacques C, Herait P: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
12. Giaccheti S, Perpoint B, Zidani R, Le Bail N, Faggivolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as a first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
13. Stathopoulos GP, Stergiou GS, Golematis B, Thalassinos N, Fillipakis M: Effects of adriamycin 5-fluorouracil and mitomycin-C combination chemotherapy in advanced colorectal cancer. Oncology 1995; 54: 306-309.
14. De Grammont A, Bosset JF, Milan C, Rougier F, Bouche O, Etienne P-L, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L: Randomized trial comparing monthly lowdose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 1997; 15: 808-815.
15. Douillard J-Y, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandi KP, Iveson T, Carmichael J, Alaki M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000; 355: 1041-1047.
16. De Gramont A, Figer A, Seymour M, Homerin F, Hmissi A, Cassidy J, Boni C, Cortes- Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
17. Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenaver A, Depisch D: Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307-1312.
18. Souglakos J, Mavroudis D, Kakolyris S, Kouroussis CH, Vardakis N, Androulakis N, Angelaki S, Kalbakis K, Tsetis D, Athanasiadis N, Samonis G, Georgoulias V: Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 2002; 20: 2651-2657.
19. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz H, Kabbinaver F, Novotny WF, Hillan KJ, Koeppen H: Association of K-ras, b-raf and p-53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97; 13: 981-989.
20. Giantonio Bruce J, Katalano PJ, Meropol NJ, O' Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AIB III: Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E 3200. J Clin Oncol 2007; 25: 1539-1544.
21. Saltz LA, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T-S, Rivera F, Couture F, Sirzèn F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
22. Sandler A, Herbst R: Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 2006; 12: 4221s-4425s.
23. Grothey A, Sugrue MM, Pardie DM, Dong W, Sergeant D, Hedrick E, Kozloff M: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRITE). J Clin Oncol 2008; 26: 5326-5334.
24. ICH Efficacy EG (R1) Good Clinical Practice Consolidated Guidelines. http://ich.org/ cache/compo/475-175.html.
25. Arbuck SG, Ivy SP, Setser A: The Revised Common Toxicity Criteria: Version 2.0. http://ctep.info.nih.gov.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors, European Organisation for Research and Treatment of Cancer, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
27. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 (suppl 3):4-10.
28. Ellis LM, Haller DG: Bevacizumab beyond progression: does this make sense? Editorial. J Clin Oncol 2009; 3: 1-3.
29. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (5-fluorouracil)/leucovorin (LV) with 5-fluorouracil/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
30. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T-S, Rivera F, Couture F, Sirzèn F, Saltz L: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
31. Stathopoulos GP, Rigatos SK, Malamos NA, Stathopoulos JG, Thallasinou P, Papazachariou E, Antoniou F, Kondopodis E, Xynotroulas G: Long-term survival of patients with advanced colorectal cancer may not be due to the response to chemotherapy. Oncology Rep 2004; 12: 1295-1300.